Opportunity Information: Apply for RFA CA 13 007
Apply for RFA CA 13 007
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Collaborative Human Tissue Network (CHTN) (UM1)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394 Cancer Detection and Diagnosis Research.
- This funding opportunity was created on Feb 21, 2013 and posted on Feb 21, 2013.
- Applicants must submit their applications by May 31, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $5,800,000.00 to eligible and selected applicants.
- Each selected applicant is eligible to receive up to $1,200,000.00 in funding.
- Eligible applicants include: State governments Others (see text field entitled Additional Information on Eligibility for clarification) Public and State controlled institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession Non domestic (non U.S.) Entities (Foreign Institutions) are not eligible to apply. Non domestic (non U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), issued this Funding Opportunity Announcement (FOA) to support the Collaborative Human Tissue Network (CHTN) through a cooperative agreement mechanism (UM1). The central purpose of the program is to maintain and operate a national biospecimen resource that can reliably provide high-quality human tissue specimens to investigators conducting basic cancer biology studies and early-stage translational cancer research. What makes CHTN distinct from many biorepositories is its emphasis on prospective, request-driven collection, meaning tissues are collected and distributed in response to specific needs defined by researchers rather than relying only on pre-banked, already-stored samples.
The scope of biospecimens covered under the CHTN is broad and intentionally designed to support a wide range of cancer-related investigations. The network is expected to collect and provide tissues from patients that include precancerous lesions, malignant (cancerous) tissues, and benign neoplastic tissues. It also extends beyond tumors by including specimens from non-neoplastic diseases and matched or uninvolved tissues, which are often essential for comparison studies, biomarker development, assay validation, and understanding disease progression. By enabling access to these different tissue categories, the CHTN supports studies that require carefully selected specimen types, clinically relevant context, and consistent quality suitable for downstream molecular and cellular analyses.
From an administrative and funding standpoint, this opportunity (Funding Opportunity Number RFA-CA-13-007) was categorized as discretionary funding and uses the cooperative agreement model, which typically indicates substantial scientific or programmatic involvement by the NIH/NCI during the award period compared to a standard grant. The activity category is listed under education/health, and it is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research). Cost sharing or matching is not required, lowering barriers for qualified institutions to apply and operate the program in alignment with NCI expectations.
The FOA was posted on February 21, 2013, with an original and current closing date of May 31, 2013, and it was later archived on July 1, 2013. The estimated total funding level for the opportunity was approximately $5,800,000, with an award ceiling of $1,200,000, indicating the program anticipated multiple awards or a structured distribution of funds across participating components consistent with a networked resource model. As a national infrastructure-style biospecimen program, these funding levels reflect the operational demands of coordinating specimen acquisition, processing, quality control, storage, documentation, and distribution to external investigators.
Eligibility was broad across U.S.-based organizations that could credibly support the required infrastructure and compliance responsibilities. Eligible applicants included state governments, public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits, other than higher education institutions). The FOA also explicitly recognized eligibility for several institution types that serve specific populations, including Alaska Native and Native Hawaiian Serving Institutions, Hispanic-Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs), as well as U.S. territories or possessions. At the same time, the opportunity clearly restricted foreign participation: non-U.S. entities were not eligible to apply, non-U.S. components of U.S. organizations were not eligible, and foreign components (as defined by NIH policy) were not allowed. These constraints reflect the program’s focus on U.S.-based clinical and regulatory environments for human tissue procurement and distribution.
Operationally, the CHTN program is intended to function as a service-oriented resource for the wider cancer research community. The emphasis on prospectively collecting tissues based on investigator specifications implies that awardees must be able to coordinate with clinical sites and pathology services, manage consent and ethical requirements, document specimen provenance and associated source information, and meet expectations for biospecimen quality and timeliness. The overall goal is to reduce a major bottleneck in cancer research by providing investigators with access to well-characterized human tissues that are fit for purpose, enabling more reproducible experiments and accelerating the pace at which early translational findings can be generated and validated.
For applicants or stakeholders who needed the full text of the announcement, the FOA provided an additional information link hosted on the NIH grants site. The contact information included the NIH Office of Extramural Research (OER) webmaster addresses for technical issues accessing the announcement or troubleshooting links, underscoring that the primary point of contact listed was oriented toward electronic access support rather than programmatic scientific questions.
Frequently Asked Questions (FAQs)
What is this funding opportunity about?
This Funding Opportunity Announcement (FOA) from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), supports the Collaborative Human Tissue Network (CHTN). The program is intended to maintain and operate a national biospecimen resource that can reliably provide high-quality human tissue specimens to investigators conducting basic cancer biology studies and early-stage translational cancer research.
What makes the CHTN different from many other biorepositories?
The CHTN emphasizes prospective, request-driven collection. That means tissues are collected and distributed in response to specific needs defined by researchers, rather than relying only on pre-banked (already stored) specimens.
What is the main purpose of the CHTN program?
The central purpose is to reduce a major bottleneck in cancer research by providing investigators with access to well-characterized human tissues that are fit for purpose, supporting more reproducible experiments and helping accelerate early translational research.
What types of research does this program support?
It supports basic cancer biology studies and early-stage translational cancer research by enabling access to high-quality human tissue specimens suitable for downstream molecular and cellular analyses.
What kinds of biospecimens is the CHTN expected to collect and provide?
The scope is broad and includes tissues from patients that cover precancerous lesions, malignant (cancerous) tissues, and benign neoplastic tissues. It also includes specimens from non-neoplastic diseases and matched or uninvolved tissues that are important for comparison studies.
Why are matched or uninvolved tissues included?
Matched or uninvolved tissues are often essential for comparison studies, biomarker development, assay validation, and understanding disease progression.
How is this opportunity funded and what mechanism is used?
This FOA uses a cooperative agreement mechanism (UM1). A cooperative agreement typically indicates substantial scientific or programmatic involvement by NIH/NCI during the award period compared to a standard grant.
What is the Funding Opportunity Number?
The Funding Opportunity Number is RFA-CA-13-007.
Is this considered discretionary funding?
Yes. The FOA was categorized as discretionary funding.
What is the activity category for this opportunity?
The activity category is listed under education/health.
What CFDA number is associated with this program?
This opportunity is associated with CFDA 93.394 (Cancer Detection and Diagnosis Research).
Is cost sharing or matching required?
No. Cost sharing or matching is not required.
When was the FOA posted and when did it close?
The FOA was posted on February 21, 2013. The original and current closing date listed was May 31, 2013.
Is this FOA still active?
No. It was later archived on July 1, 2013.
How much total funding was estimated for this opportunity?
The estimated total funding level was approximately $5,800,000.
What was the award ceiling?
The award ceiling was $1,200,000.
Does the funding information suggest multiple awards?
Yes. The combination of an estimated total funding level of about $5,800,000 and an award ceiling of $1,200,000 suggests the program anticipated multiple awards or a structured distribution of funds across participating components consistent with a networked resource model.
Who is eligible to apply?
Eligibility was broad across U.S.-based organizations capable of supporting the needed infrastructure and compliance responsibilities. Eligible applicants included state governments, public and state-controlled institutions of higher education, private institutions of higher education, and nonprofit organizations (including both 501(c)(3) and certain non-501(c)(3) nonprofits, other than higher education institutions).
Are minority-serving institutions included in the eligible applicants?
Yes. The FOA explicitly recognized eligibility for Alaska Native and Native Hawaiian Serving Institutions, Hispanic-Serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs).
Are U.S. territories or possessions eligible?
Yes. The FOA recognized eligibility for U.S. territories or possessions.
Are foreign organizations eligible to apply?
No. Non-U.S. entities were not eligible to apply.
Can a U.S. organization include a non-U.S. component?
No. Non-U.S. components of U.S. organizations were not eligible.
Are foreign components allowed under NIH policy for this FOA?
No. Foreign components (as defined by NIH policy) were not allowed.
What does it mean that the CHTN operates as a service-oriented resource?
It means the network is intended to provide biospecimens to the wider cancer research community, with an operational focus on meeting investigator needs through request-driven, prospectively collected tissues.
What operational capabilities are implied by prospective, request-driven tissue collection?
The FOA implies awardees must be able to coordinate with clinical sites and pathology services, manage consent and ethical requirements, document specimen provenance and associated source information, and meet expectations for biospecimen quality and timeliness.
What kinds of activities do the funding levels reflect for a national biospecimen resource?
As described, the funding levels reflect operational demands such as coordinating specimen acquisition, processing, quality control, storage, documentation, and distribution to external investigators.
Where could applicants find the full text of the announcement?
The FOA provided an additional information link hosted on the NIH grants site.
Who was listed as a contact for technical issues?
The contact information included NIH Office of Extramural Research (OER) webmaster addresses for technical issues accessing the announcement or troubleshooting links.
Was programmatic scientific contact information emphasized in the provided details?
Based on the information provided, the primary point of contact described was oriented toward electronic access support rather than programmatic scientific questions.
Browse more opportunities from the same category: Education Health
Next opportunity: FMI New Mexico Mines NRDA Restoration Plan and Enviromental Assessment
Previous opportunity: Limited Competition Extramural Research Facilities Improvement Program (C06)
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 13 007
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 13 007) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on Marijuana Legalization in the US (Admin Supp) Apply for PA 13 138 Funding Number: PA 13 138 Agency: National Institutes of Health Category: Education Health Funding Amount: $250,000 |
| Lasker Clinical Research Scholars Program (Si2) Apply for RFA OD 13 004 Funding Number: RFA OD 13 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Limited Competition Multicenter AIDS Cohort Study Center for the Coordination, Analysis, and Management of the MACS (CAMACS)(UM1) Apply for RFA AI 13 010 Funding Number: RFA AI 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: $2,400,000 |
| Limited Competition Multicenter AIDS Cohort Study (MACS) Clinical Research Sites (U01) Apply for RFA AI 13 011 Funding Number: RFA AI 13 011 Agency: National Institutes of Health Category: Education Health Funding Amount: $4,200,000 |
| Limited Competition Scholars Training for the Advancement of Research (STAR) Revision to NINR T32 Training Grants (T32) Apply for RFA NR 13 010 Funding Number: RFA NR 13 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NCI Exploratory/Developmental Research Grant Program (NCI Omnibus R21) Apply for PAR 13 146 Funding Number: PAR 13 146 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Advancing Exceptional Research on HIV/AIDS (R01) Apply for RFA DA 14 003 Funding Number: RFA DA 14 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21) Apply for PA 13 157 Funding Number: PA 13 157 Agency: National Institutes of Health Category: Education Health Funding Amount: $175,000 |
| Development and Application of PET and SPECT Imaging Ligands as Biomarkers for Drug Discovery and for Pathophysiological Studies of CNS Disorders (R21/R33) Apply for PAR 13 158 Funding Number: PAR 13 158 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| NIDA Mentored Clinical Scientists Development Program Award in Drug Abuse and Addiction (K12) Apply for PAR 13 163 Funding Number: PAR 13 163 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R01) Apply for PA 13 165 Funding Number: PA 13 165 Agency: National Institutes of Health Category: Education Health Funding Amount: $350,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R15) Apply for PA 13 166 Funding Number: PA 13 166 Agency: National Institutes of Health Category: Education Health Funding Amount: $300,000 |
| Innovative Research Methods Prevention and Management of Symptoms in Chronic Illness (R21) Apply for PA 13 167 Funding Number: PA 13 167 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| The Role of Microbial Metabolites in Cancer Prevention and Etiology (U01) Apply for PAR 13 159 Funding Number: PAR 13 159 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Academic Industrial Partnerships for Translation of in vivo Imaging Systems for Cancer Investigations (R01) Apply for PAR 13 169 Funding Number: PAR 13 169 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Drug Abuse Dissertation Research (R36) Apply for PAR 13 182 Funding Number: PAR 13 182 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Collaborative Research in Integrative Cancer Biology (U01) Apply for PAR 13 184 Funding Number: PAR 13 184 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Image guided Drug Delivery in Cancer (R01) Apply for PAR 13 185 Funding Number: PAR 13 185 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R01) Apply for RFA MH 14 170 Funding Number: RFA MH 14 170 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Eradication of HIV 1 from CNS Reservoirs Implications for Therapeutics (R21) Apply for RFA MH 14 171 Funding Number: RFA MH 14 171 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 13 007", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.